A synthesised four-amino-acid peptide from the Khavinson bioregulator programme, directed at pancreatic tissue.

Why is the pancreas described as doing two jobs?

Because it runs two unrelated operations. Most of it produces digestive enzymes released into the gut. Small clusters of cells within it — the islets — produce insulin and glucagon and release them into the blood to regulate blood sugar.

How strong is the evidence?

Limited — small, preclinical and largely from the originating institute, with no regulatory approval anywhere.

Why is the pancreas described as two organs?

Because it runs two unrelated operations from the same tissue. The larger one produces digestive enzymes and pipes them into the intestine; the smaller produces hormones including insulin and glucagon and releases them into the bloodstream. Different cells, different products, different destinations.

Why is the pancreas vulnerable to its own enzymes?

Because the digestive enzymes it makes are powerful enough to dissolve tissue. They are manufactured in a deliberately inactive form and only switched on after leaving the organ. When that safeguard fails the pancreas begins digesting itself, which is what pancreatitis is.

Research Library›Bioregulators & Neuropeptides›Pancragen

Pancreatic Bioregulator

Pancragen: The Peptide for an Organ Doing Two Jobs

A four-amino-acid sequence aimed at pancreatic tissue — an organ that runs two entirely separate operations out of the same building.

5 min read·4 studies cited·Updated July 2026

Evidence level

Preclinical only — animal and cell studies

What this level means

Quick Reference

Sequence	Lys-Glu-Asp-Trp (KEDW)
Target tissue	Pancreas
Generation	Synthetic (second-generation)
Family	Khavinson bioregulators

What Is Pancragen?

Pancragen is a synthesised tetrapeptide from the Khavinson family, directed at the pancreas. The name follows the family convention, from pancreas.

The pancreas’s double life, in plain language: most organs have one job. The pancreas has two, and they have almost nothing to do with each other. The bulk of it is a factory producing digestive enzymes, pumped into the gut to break down food. Scattered through that factory are small islands of entirely different cells — the islets — producing insulin and glucagon and releasing them into the blood to govern blood sugar. It is as though a bakery had, dotted between its ovens, a handful of desks quietly running the national bank. Two operations, one building, shared plumbing. Research interest in the pancreas is usually aimed at the islands rather than the bakery.

What the Research Examines

Published work examines Pancragen in connection with pancreatic tissue function, including markers associated with islet cells and carbohydrate metabolism in animal models.

The evidence base is small and preclinical, originating chiefly from the developing institute, with no regulatory approval in any jurisdiction.

Two Businesses in One Building

The pancreas is really two organs sharing an address, and they have almost nothing to do with each other.

The larger operation makes digestive enzymes — powerful ones, capable of breaking down protein, fat and starch — and pipes them into the intestine. The smaller operation makes hormones, insulin and glucagon among them, and releases them into the bloodstream to regulate blood sugar. Different cells, different products, different destinations.

Picture a building where a chemical works and a telephone exchange share the same premises. One ships barrels out by road; the other sends messages down wires. Neither needs the other, and the only thing they have in common is the roof.

There is a real hazard in that arrangement. The digestive enzymes are made in a form powerful enough to dissolve tissue, so they are manufactured deliberately inactive and only switched on after they leave. The factory builds the machinery disassembled, because assembling it on site would destroy the site. When that safeguard fails, the pancreas begins digesting itself — which is what pancreatitis is.

Both operations sit in the same tissue, which is why research aimed at the pancreas has to be clear about which of the two businesses it is talking about.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Khavinson VK, Malinin VV. “Gerontological Aspects of Genome Peptide Regulation.” Karger AG, Basel, 2005. Source
Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology, 2010. PubMed
Khavinson VKh. “Peptides and Ageing.” Neuro endocrinology letters, 2002. PubMed
Fedoreyeva LI, Kireev II, Khavinson VKh, et al. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry. Biokhimiia, 2011. PubMed